1. Home
  2. Labeler Index
  3. Physician Therapeutics Llc
  4. NDC Product Code: 68405-007 Lytensopril-90

NDC 68405-007 Lytensopril-90

View Dosage, Usage, Ingredients, Routes, UNII

Table of Contents

  1. Product Information
  2. Product Packages
  3. Product Characteristics
  4. What is NDC 68405-007?
  5. Lytensopril-90 Uses
  6. Active Ingredients UNII Codes
  7. Inactive Ingredients UNII Codes
  8. NDC to RxNorm Crosswalk

Product Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
NDC Product Code:
68405-007
Proprietary Name:
Lytensopril-90
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Labeler Name: [5]
Physician Therapeutics Llc
Labeler Code:
68405
Product Label ID:
787c1115-61fa-41d1-a0b2-32318f1e20f5
Start Marketing Date: [9]
07-07-2011
Listing Expiration Date: [11]
12-31-2017
Exclude Flag: [12]
I
Code Navigator:

Product Characteristics

Color(s):
PINK (C48328 - PINK)
WHITE (C48325 - WHITE)
Shape:
ROUND (C48348)
CAPSULE (C48336)
Size(s):
8 MM
21 MM
Imprint(s):
LUPIN;20
;
Score:
1

Code Structure Chart

Product Details

What is NDC 68405-007?

The NDC code 68405-007 is assigned by the FDA to the product Lytensopril-90 which is product labeled by Physician Therapeutics Llc. The product's dosage form is . The product is distributed in a single package with assigned NDC code 68405-007-36 1 kit in 1 kit * 90 capsule in 1 bottle * 30 tablet in 1 bottle (52959-729-30). This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

What are the uses for Lytensopril-90?

INDICATIONS AND USAGEHypertensionLisinopril Tablets are indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.Heart FailureLisinopril Tablets are indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis.Acute Myocardial InfarctionLisinopril Tablets are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers.In using Lisinopril Tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that Lisinopril Tablets do not have a similar risk.(See WARNINGS.)In considering the use of Lisinopril Tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients. (See WARNINGS, Anaphylactoid and Possibly Related Reactions.) INDICATIONS FOR USE  Hypertensa is intended for the clinical dietary management of the metabolic processes in patients with hypertension.

Which are Lytensopril-90 UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are Lytensopril-90 Inactive Ingredients UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for Lytensopril-90?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct code indicates a single concept unique identifier (RXCUI) is associated with this product:

* Please review the disclaimer below.

Product Footnotes

[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".